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O b j e c t i v e.  The aim of the study was to determine the populational and clinical features of mucinous breast carcinoma, to
determine specific features of mucinous breast carcinoma by immunohistochemical evaluation, to assess prognostic factors,
with special consideration to MIB-1 proliferation factor, as well as p53 gene and c-erb B2 expressions, to assess the effective-
ness of operative treatment and the causes of its failure and to determine the optimal method of adjuvant therapy.
M a t e r i a l.  The group of 81 patients with mucinous breast carcinoma who received initial surgery between 1952 and 1993
was studied. The age was 30-84, mean 62. The duration of symptoms ranged from 1 to 35 months, mean 8. Fifty patients
(61.7%) presented the pure and 31 patients – (38.3%) mixed type of carcinoma.
Re s u l t s.  The actuarial 10-year overall and symptom-free survival was 60.5% (74.0% for pure and 39.0% for mixed type of
cancer). Statistically significant better chance of 10-year survival without cancer was observed in women over sixty years of age,
menopausal or postmenopausal, with no involvement of axillary nodes, in stage I and IIA, with lump size under 4 cm, micro-
scopically negative axillary nodes, and pure mucinous type. Patients whose tumours did not present p53 expression, had sta-
tistically significant better chance of disease–free 10-year survival. In the sub-group of 50 patients with pure type carcinoma,
statistically significant better disease–free 10-year survival was obtained in patients with clinically and microscopically nega-
tive axillary nodes, and whose tumours revealed no p53 expression. In the sub-group of 31 patients with mixed type carcino-
ma, statistically significant chance of 10-year survival without cancer was observed in patients over sixty, menopausal or post-
menopausal. None of the immuno-histochemically evaluated discriminants showed statistically significant impact on disease-
-free survival in this group. The following factors in the entire group of patients were responsible for statistically significant,
unfavourable impact on 10- year survival without cancer: mixed type, age below 60, and clinical axillary involvement. In the
group of patients with pure type carcinoma, statistically significant, unfavourable influence on 10-year disease-free survival was
exerted solely by the clinical presence of N2 metastases to axillary nodes. In the group of patients with mixed type, only the pa-
tients' age <60 had an unfavourable effect on 10-year survival without cancer. The specific populational and clinical featu-
res of mucinous breast carcinoma were: mean age – 62 years (30-84), over 3/4 of patients being menopausal or postmenopau-
sal, mean time of symptoms duration – 8 months (1-36), most common localisation of tumour in the outer quadrants of the
breast,  lump size in the breast (pT) not exceeding 4 cm, in over 70% of patients, microscopically negative axillary nodes in over
60% of patients. The specific features found by immunuhistochemical evaluations were: relatively low MIB-1 index which
in over half of the patients did not exceed 14 (2-46), over 90% of patients being oestrogen receptor positive and over 60% –
progesterone receptor positive, low percentage of tumours presenting p53 and c-erb B2 expression – 12.3% and 9.9% respec-
tively.
C o n c l u s i o n s.  Independent, unfavourable prognostic factors in patients with mucinous breast carcinoma are: age below
60, clinically established presence of axillary metastases and the mixed type of disease. Surgical treatment allows to obtain over
60% of 10-year cancer free survival in patients with mucinous carcinoma of the breast, of which 74% in the pure, and 39%
in the mixed mucinous type group. The basic cause of treatment failure is generalisation of the malignant process. All patients
with mixed mucinous breast carcinoma type and those with pure mucinous type who are axillary positive should receive the
same treatment as patients with ductal infiltrating carcinoma at the corresponding stage of clinical advancement, both local
and adjuvant. For patients with pure mucinous breast carcinoma type and negative axillary nodes, breast conservation treat-
ment should be the main option, eventually without adjuvant systemic therapy.
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Introduction
According to many authors, mucinous carcinoma consti-
tutes 1-5% of malignant tumours of the breast [1-17).
Mucinous carcinoma of the breast is a disease of women,
although rare cases of its appearance in males have been
reported.
There is a prevailing opinion that mucinous carcino-
ma is found in older women, when compared with other
microscopically detected breast cancers [1, 2, 4, 8-10, 18-
Analiza skutecznoÊci leczenia chirurgicznego oraz czynników prognostycznych
u chorych na Êluzowatego raka sutka
W s t ´ p.  Rak Êluzowaty sutka (RSS) stanowi wg ró˝nych autorów 1-5% nowotworów z∏oÊliwych sutka. Wyró˝nia si´ dwie po-
stacie histologiczne RSS: czystà oraz mieszanà. RSS jest powszechnie zaliczany do grupy tzw. „lepiej rokujàcych” postaci ra-
ka sutka.
C e l  p r a c y.  OkreÊlenie charakterystycznych cech populacyjnych i klinicznych RSS, okreÊlenie charakterystycznych cech RSS
w dost´pnych badaniach immunohistochemicznych, ocena czynników prognostycznych u chorych na RSS, ze szczególnym
uwzgl´dnieniem: wskaênika proliferacji MIB-1 i ekspresji genu p53 i c-erb B-2, ocena skutecznoÊci leczenia chirurgicznego
i przyczyn jego niepowodzenia, próba okreÊlenia optymalnego sposobu leczenia adiuwantowego chorych na RSS.
M a t e r i a ∏.  Przedmiotem szczegó∏owej analizy jest grupa 81 chorych na RSS, leczonych pierwszorazowo chirurgicznie
w COOK w okresie 1952-1993 r. Najm∏odsza chora liczy∏a 30 lat, najstarsza 84 lata, Êredni wiek wynosi∏ 62 lata. Czas
trwania objawów chorobowych waha∏ si´ od 1-35 miesi´cy, Êrednio wynosi∏ 8 miesi´cy. U 50 chorych (61,7 %) rozpoznano
czystà, a u 31 (38,3 %) mieszanà postaç RSS.
W y n i k i.  W badanej grupie 81 chorych na RSS prognozowane 10-letnie prze˝ycie ca∏kowite i bezobjawowe wynios∏o
60,5%, na czystà postaç 74,0 %, na postaç mieszanà 39,0 %. Statystycznie znamienne wy˝sze szanse bezobjawowego 10-let-
niego prze˝ycia majà chore: powy˝ej 60 roku ˝ycia, w trakcie i po menopauzie, bez klinicznie podejrzanych w´z∏ów ch∏on-
nych pachy, w I i II A stopniu zaawansowania raka wg TNM, z guzem w sutku (pT) nie przekraczajàcym 4 cm, mikrosko-
powo bez przerzutów w w´z∏ach ch∏onnych pachowych, z czystà postacià RSS. Statystycznie znamiennie wy˝szà szans´ bez-
objawowego 10-letniego prze˝ycia mia∏y chore, u których guz nie wykazywa∏ ekspresji genu p53. W grupie 50 chorych na czystà
postaç RSS statystycznie znamienne wy˝sze bezobjawowe 10-letnie prze˝ycie uzyskano u chorych: bez klinicznie podejrzanych
w´z∏ów ch∏onnych w pasze i bez mikroskopowo stwierdzonych przerzutów w tych w´z∏ach oraz u chorych, u których guz nie
wykazywa∏ ekspresji genu p53. W grupie 31 chorych na mieszanà postaç RSS statystycznie znamiennie wy˝szà szans´ bezob-
jawowego 10-letniego prze˝ycia mia∏y chore powy˝ej 60 roku ˝ycia i w trakcie lub po menopauzie. ˚aden ze wskaêników ba-
danych immunohistochemicznie nie wykaza∏ statystycznie znamiennego wp∏ywu na prze˝ycie bezobjawowe w tej grupie. W ca-
∏ej badanej grupie chorych znamienny statystycznie, niekorzystny wp∏yw na 10-letnie prze˝ycie bezobjawowe w wieloce-
chowym modelu Coxa, mia∏y: mieszana postaç RSS, wiek chorych poni˝ej 60 roku ˝ycia i klinicznie stwierdzona obecnoÊç
przerzutów w w´z∏ach ch∏onnych pachowych. W grupie chorych na czystà postaç RSS, znamienny statystycznie, nieko-
rzystny wp∏yw na 10-letnie prze˝ycie bezobjawowe w wielocechowym modelu Coxa ma jedynie klinicznie stwierdzona obec-
noÊç przerzutów do w´z∏ów ch∏onnych pachowych o zaawansowaniu N2. W grupie chorych na mieszanà postaç RSS,
znamienny statystycznie, niekorzystny wp∏yw na 10-letnie prze˝ycie bezobjawowe, w wielocechowym modelu Coxa, ma jedy-
nie wiek chorych poni˝ej 60 roku ˝ycia. Charakterystyczne cechy populacyjne i kliniczne RSS, stwierdzone w badanej grupie
chorych to: a) Êredni wiek 62 lata (30-84), b) ponad 3/4 chorych w trakcie i po okresie menopauzy, c) Êredni czas trwania ob-
jawów chorobowych 8 miesi´cy (1-36), d) najcz´stsza lokalizacja guza w kwadrantach zewn´trznych sutka, e) u ponad
70% chorych guz w sutku (pT) nie przekraczajàcy 4 cm, f) u ponad 60% chorych mikroskopowo stwierdzony brak przerzu-
tów w w´z∏ach ch∏onnych pachowych. Charakterystyczne cechy RSS w wykonanych badaniach immunohistochemicznych to:
a) stosunkowo niski wskaênik MIB-1, u ponad po∏owy chorych nie przekraczajàcy 14 (2-46), b) u ponad 90% chorych obec-
noÊç receptora estrogenowego i u ponad 60% progesteronowego, c) niski odsetek guzów wykazujàcych ekspresj´ genu p53 i c-
-erb B2, odpowiednio 12,3% i 9,9%.
W n i o s k i.  Niezale˝nymi, niekorzystnymi czynnikami prognostycznymi u chorych na RSS sà: wiek chorych poni˝ej 60 roku
˝ycia, klinicznie stwierdzona obecnoÊç przerzutów w w´z∏ach ch∏onnych pachowych oraz mieszana postaç RSS.
Leczenie chirurgiczne pozwala na uzyskanie ponad 60% 10-letnich prze˝yç bezobjawowych u chorych na RSS, w tym 74%
w grupie chorych na czystà i 39% na mieszanà postaç RSS. Podstawowà przyczynà niepowodzenia leczenia jest uogólnienie
procesu nowotworowego.
Wszystkie chore na mieszanà postaç RSS oraz chore na czystà postaç RSS z przerzutami do w´z∏ów ch∏onnych pachowych win-
ny byç leczone tak samo, jak chore na RPN, w odpowiednim stopniu zaawansowania klinicznego, zarówno miejscowo, jak
i uzupe∏niajàco.
U chorych na czystà postaç RSS, bez przerzutów do w´z∏ów ch∏onnych pachowych, nale˝y przede wszystkim rozwa˝yç lecze-
nie chirurgiczne, oszcz´dzajàce sutek i ewentualnie rezygnacj´ z adiuwantowego leczenia systemowego.
Key words: mucinous carcinoma of the breast, prognostic factors, cancer free survival
S∏owa kluczowe: rak Êluzowaty sutka, czynniki prognostyczne, prze˝ycia bezobjawowe
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-20]. Berg and Hutter, basing on the data obtained from
the SEER (Surveillance, Epidemiology and End Results)
Register of the American National Cancer Research Insti-
tute, showed that the mean age of patients with mucinous
carcinoma of the breast exceeded by 9-11 years the mean
age of patients with infiltrating ductal carcinoma, and
that the prevalence of mucinous carcinoma of the bre-
ast grew dramatically in women over 60 years of age. Ro-
sen et al. found that it constituted 1 % in the group of
cancer patients below 35 years of age, and 7% in those
over 75 years of age.
According to the definition of the World Health Or-
ganisation, mucinous carcinoma of the breast is a mali-
gnancy containing a large amount of extracellular mucin
visible on gross examination which is also present within
the cancerous cells. In English language literature, the
term most commonly used in relation to this malignancy
is “mucinous carcinoma” although other terms, such as
“gelatinous”, “colloid, ‚mucous’ or ‚mucoid carcinoma’
are also applied [8, 10, 20].
Two types of mucinous carcinoma of the breast have
been described: pure and mixed. The pure type involves
tumours which are fully built of isolated small islands of
continuous cancerous tissue ‚floating’ in abundant extra-
cellular mucin. Mixed type tumours, have additional are-
as of infiltrating carcinoma with no extracellular mucin
present [4, 8-10, 20, 22]. Mucinous carcinoma of the bre-
ast was first described in 1826 and we owe detailed evalu-
ation of its microscopic features and clinical outcome to
such authors as: Robinson (1852), Larey (1853), Lange
(1896), Gaabe (1908), Halsted (1915), Geschickter (1930
and 1938), Saphir (1941) [6].
In 1980, Capella et al. made an attempt at subtyping
mucinous carcinoma of the breast, and distinguished three
types: type A-built of cancerous cells slightly more ple-
omorphic than type B, arranged in small groups floating in
abundant extracellular mucin, and routinely with the ab-
sence of mucin within the cells; type B-built of more mo-
nomorphic cancerous cells, arranged in larger clusters,
with smaller amount of extracellular mucin, but with the
occasional presence of mucin within the cells; the over-
whelming majority of B-type tumours being argentophilic;
type AB, sharing the characteristics of the other two and
the rarest of the three [2, 6, 9, 20, 23]. The investigations by
Scopsi et al. Showed, however, that this division is of no
prognostic significance, while such significance is provi-
ded by the division into pure and mixed types [2, 8, 9, 24].
Mucinous breast carcinoma generally counts among
the ‚better prognosing’ types of breast cancer [2, 8, 9, 20,
22, 25]. Particularly good prognosis is associated with pu-
re type [1, 2, 4, 10, 23, 24, 26-29], where metastases to
regional lymph nodes are uncommon (8, 10, 20) and long
term survival reaches, and even exceeds 90% [4, 24, 30-
-32]. Better prognosis in the group of women with pure
mucinous carcinoma type in comparison with infiltrating
ductal carcinoma patients, has been also proved in a num-
ber of indirect observations. Toikkanen et al., found that
in the group of women with breast cancers who survived
10 years, there was a higher percentage of mucinous car-
cinoma cases, as compared to the entire population. In
the group of women who were alive 20 years after treat-
ment, MituÊ et al. found a higher percentage of mucinous
carcinoma cases (9.4%) as compared with a model group
of breast cancer patients presented by Henderson (2.4%).
Both Toikkanen et al. and Dixon et al. stress that 10 years
after surgery, late recurrence of mucinous carcinoma is
much rarer than of infiltrating ductal carcinoma of the
breast [27]. Andersen et al. reported higher percentage of
mucinous carcinoma of the breast among disease-free
patients in whom breast cancer was screened, as compa-
red to the entie population.
According to a majority of authors, the clinical out-
come and prognosis in the mixed type of mucinous carci-
noma of the breast were similar as in the infiltrating duc-
tal carcinoma [8, 22].
A detailed histological examination is obviously of
basic importance for diagnosing mucinous carcinoma of
the breast. Fine needle aspiration biopsy is generally a hi-
ghly useful method of detecting breast cancers, and
among them, mucinous breast carcinoma [4, 20, 21, 34,
35]. Nevertheless, in order to obtain detailed characteri-
stics of a tumour and to distinguish the pure or mixed
type of mucinous carcinoma of the breast, not only in-
traoperative cryo-evaluation but also postoperative hi-
stologic assessment is necessary [4, 20, 35].
Visualising examinations are of supportive value in
diagnosing mucinous carcinoma of the breast [4, 20, 36,
37, 38]. On ultrasound imaging, mucinous breast carcino-
ma usually presents as a well defined round or oval mass
with hypogenous echo pattern [37]. Mammography gene-
rally visualises a single round or oval mass of lobular
structure [36]. In the pure form the mass is well defined,
and in the mixed type its contour is commonly irregular
[4]. Calcium deposits are found in 20-40% of patients
[20, 37].
Objective of the study
– To determine specific population and clinical features
of mucinous breast carcinoma,
– To determine specific features of mucinous breast car-
cinoma in available immunohistochemical evaluations,
– To assess the prognosticators in mucinous breast carci-
noma patients, with special consideration to MIB-1
proliferation factor as well as p53 gene and c-erb B2
expressions,
– To assess the effectiveness of operative treatment and
of the causes of its failure,
– To determine the optimum method of adjuvant the-
rapy in patients with mucinous breast carcinoma.
Methods
The methodics have been based on a retrospective analysis of the
clinical material involving 81 patients with mucinous carcino-
ma of the breast who had received initial surgical treatment at
the Cracow Branch of the Oncology Centre from 1952 to 1993.
The basic data about the patients was obtained from clini-
cal records, but other sources such as letters referring patients
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for treatment, case reports from other therapeutic institutions,
and letters written by patients or their families have also been
used. Information on the date of death was obtained, in wri-
ting, from families or state agencies dealing with population
statistics. The follow-up covered 100% of patients.
Over the above mentioned period of time, 3740 women
with breast cancer received initial surgical treatment in the Cra-
cow Branch of the Oncology Centre. 81 of them, i.e. 2.2%, were
diagnosed with mucinous carcinoma of the breast. The microsco-
pic status of all tumours was reanalysed in detail. In each case,
a histological diagnosis of mucinous carcinoma was based on
the criteria complying with the WHO classification. On micro-
scopic assessment of tumour specimens pure and mixed types of
mucinous carcinoma were distinguished. Typed as pure, were
tumours showing no presence of infiltrating ductal carcinoma
component (or lobular infiltrating carcinoma) following the cri-
teria suggested by Norris and Taylor. Typed as mixed, were all tu-
mours in which, apart from mucinous carcinoma, there was ad-
ditional presence of infiltrating ductal or lobular lesions. In no-
ne of the studied cases did the additional infiltrating carcinoma
component exceed 75% of the tumour section surface.
The clinical advancement of tumour in the studied group
was evaluated according to 1997 UICC TNM system. Patients in
this group were currently staged in respect of disease advance-
ment according to the presently adopted TNM classification of
breast cancer. For the needs of this thesis the staging was expres-
sed in the system in use since 1997. All patients received initial
surgical treatment at the Cracow Branch of Oncology Centre
and it was here that an accurate microscopic analysis of the ma-
terial obtained at surgery was performed. All other therapeutic
procedures, such as postoperative irradiation and/or chemo-
-hormonotherapy were given in the same institution.
A detailed assessment of the clinical outcome of mucinous
carcinoma of the breast was made and clinical outcomes as well
as treatment results of pure and mixed types were compared.
Specific features of mucinous carcinoma of the breast were de-
termined in the available immunohistochemical evaluations. In
order to specify the prognostic factors in a given group of pa-
tients, an analysis was performed to find how the treatment re-
sults depended on population, clinical and microscopic characte-
ristics, as well as on the presence of hormonal receptors, MIB-1
proliferation index, expression of p53 and c-erb B-2. The choice
of the last three indices resulted, first of all, from the data conta-
ined in literature, suggesting or pointing to their prognostic va-
lue in malignant tumours in humans (particularly those inclu-
ding, obviously enough, patients with breast tumours) and se-
cond, from the availability of the Cancer Pathology Department
of the Cracow Branch of the Oncology Centre for making the re-
quired determinations [39-41].
Immunohistochemical determinations of the content of
MIB-1 proliferative antigen and the product of p53, c-erb B2
as well as hormonal receptors in paraffin embedded prepara-
tions, were performed in the Immunohistochemistry Laborato-
ry of the Cancer Pathology Department of the Oncology Centre.
S t a t i s t i c a l  a n a l y s i s
The criterion of treatment effecacy was a disease-free 10-year su-
rvival, counting from the date of operation. All patients were fol-
lowed up for at least five years, decease being the sole reason for
termination of follow-up. The mean follow-up time was 15 years
(5-46). The probability of 10-year survival was assessed by the
Kaplan-Meier method. Log-rank test according to Peto et al.
was used to assess the differences found in the material. P valu-
es ≤0.05. were considered statistically significant.
To assess the effect of the selected factors on the patients'
survival, Cox proportional hazard model was used [42]. At the
first stage, the influence of the analysed factors was assessed
using monovariate Cox model. For factors, the level of which was
divided into more than two classes having natural sequence (i.e.
tumour advancement acc. to TNM), the significance of relative
risk trend was also investigated. At the next stage, multivariate
analysis in reference to disease-free survival was performed,
with consideration to population, clinical and microscopic factors
as well as those evaluated by immunohistochemistry.
The final selection of the set of prognostic factors was ma-
de with the backward regression method. The effect power of the
studied prognostic factors was presented in the form of a relati-
ve hazard risk.
Many variables included in the study are of continuous
nature (i.e. age, size of tumour in the breast etc.) Therefore,
first, the Cox models were constructed which considered a given
variable in a continuous aspect, and next, optimum potential
cut points were looked for. For this purpose, two survival curves
were compared, representing values above and below the cut
point. The discriminative power of the cut point was measured
by the value of test probability p, of the log rank test comparing
the two curves.
Material
The subject of detailed analysis was a group of 81 patients with
mucinous carcinoma of the breast who had received primary
surgical treatment atthe Cracow Branch of Oncology Centre
from 1952 to 1993. The youngest patient was 30 years old and
the oldest 84; the mean age was 62 years. The time of symp-
tom duration ranged from 1 to 35 months, with a mean value of
8 months. Pure type was found in 50 (61.7%) and mixed in 31
(38.3%) of patients. In terms of statistics, women with pure type
of mucinous carcinoma of the breast were significantly older
than those with mixed type and presented significantly less com-
mon involvement of the axillary nodes. In the studied group,
the risk of positive axillary nodes was in direct correlation with
the size of tumour.
In the group of patients with tumours under 2 cm, positive
axillary nodes were found in 4.3% of patients, while in the group
with tumours over 4 cm, in as many as 91.7% of patients. The
observed differences are highly statistically significant (log rank
test p<0.01). It should be noted that among 15 patients with
pure mucinous carcinoma type and tumour size not exceeding 2
cm, none was node positive. In 43, i.e. 53.1% of patients, the
MIB-1 index was below or equal 14, and in the remaining 38, i.e.
46.9%, it exceeded this value. Expression of p53 and c-erb B2 was
rare; it was found only in 12.3% and 9.8% of patients respective-
ly. 74 i.e. 91.4% of patients were positive for oestrogen receptor
and 51, i.e. 63% of patients for progesterone receptor.
Comparing the two groups of patients, those with pure ty-
pe and those with mixed type, it has been found that:
– tumours with p53 and c-erb B2 expression were equally rare in
both groups,
– the presence of progesterone receptor was slightly, though
not significantly, more frequent in patients with pure type,
– among 31 patients with mixed type, the MIB-1 index exce-
eding 14, was presented by 19 i.e. 61.3% tumours, while
among 50 patients with pure type – 19 i.e. 38% tumours; this
difference is statistically significant (log-rank-test p<0.05),
– among 31 patients with mixed type, the presence of oestrogen
receptor was found in 25, i.e. 80.6% tumours, whereas among
50 patients with pure type – in 49, i.e. 98% tumours; this dif-
ference is also statistically significant (log-rank-test p<0.01).
Results
In the studied group of 81 patients with mucinous carcino-
ma of the breast, the overall actuarial 10-year survival
without cancer was 60.5%, as shown in Figure 1.
The actuarial 10-year cancer free survival in patients
with pure type of mucinous carcinoma of the breast was
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74.0% and in those with mixed type – 39.0%, as shown in
Figure 2.
Statistically significant higher chance of 10-year survi-
val without cancer is observed in patients: over 60 years of
age, menopausal or postmenopausal, without presence
of clinically suspected axillary lymphatic nodes, in stages
I and II A of tumour advancement according to TNM,
with mass size in the breast not exceeding 4 cm, no micro-
scopically detected metastases to axillary lymph nodes,
and with pure type of mucinous carcinoma of the breast.
A statistically significant higher chance of 10 year survival
without cancer was observed in patients with the absence
of p53 gene expression.
Table I presents treatment results in a group of
50 patients with pure type of mucinous carcinoma of the
breast by chosen population and clinical characteristics.
Table I shows that in a group of 50 patients with
pure type of mucinous carcinoma of the breast, a statisti-
cally significant higher 10-year cancer-free survival was
obtained in patients with no clinically suspected axillary
node involvement and with microscopically negative no-
des. All 15 patients with pT not exceeding 2 cm, and
with no axillary node involvement survived for 10 years wi-
thout cancer.
The results of treatment by MIB-1 index, p53 and c-erb
B2 expression, and presence of hormonal receptors in
Figure 1. Actuarial overall and cancer free 10-year survival
Figure 2. Cancer free survival by microscopic type of mucinous
carcinoma of the breast
Table I. The results of treatment of 50 patients with “pure” mucinous carcinoma of the breast, and selected populational and clinical characteristics
Population or clinical characteristics No. of treated patients Actuarial of 10-year p
cancer free survival in% (log-rank test)
* age:
under 50 8 68.6
51-60 8 72.9
over 60 34 71.7 0.8304
* menopausal status:
premenopausal 9 60.0
menopausal and postmenopausal 41 74.4 0.0861
Localisation of tumour in the breast
Outer quadrants 26 74.9
Other parts of the breast 24 70.4 0.5006
*clinical nodal status (N):
N0 23 80.9
N1 20 65.0
N2 7 34.3 0.0018
*tumour grading acc. to TNM:
I°+ II°A 21 83.6
II°B 12 75.0
III° 17 61.3 0.1913
Size of mass in the breast assessed by a pathologist 
in operation material (pT):
Up to 4 cm 36 78.4
Over 4 cm 14 64.3 0.3433
* microscopic nodal status (pN):
pN0 35 87.8
pN+(1-3) 8 45.7
pN+(>3) 7 42.9 0.0021
Total 50 74.0
* statistically significant differences, log-rank test, p<0.05
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a group of patients with pure type of mucinous breast
carcinoma are presented in Table II.
Table II shows that statistically a significant higher
chance of 10- year cancer-free survival was observed in
patients with pure type of mucinous carcinoma of the
breast, and no p53 gene expression.
Table III shows treatment results in a group of 31
patients with mixed type of mucinous carcinoma of the
breast, by selected population and clinical characteri-
stics.
Table III shows, that in a group of 31 patients with
mixed type of mucinous carcinoma of the breast, stati-
Table II. The results of treatment of 50 “pure type” patients and immunohistochemical evaluations
Discriminants No. of treated patients Actuarial 10-year p
cancer free survival (log-rank-test)
MIB-1 index
≤14 31 77.4
>14 19 68.4 0.6542
* p53 gene expression
yes 6 33.3
no 44 78.9 0.0257
c-erb B2 gene expression:
yes 4 75.0
no 46 71.0 0.9393
Oestrogen receptor:
present 49 70.2
absent 1 – 0.2758
Progesterone receptor:
present 34 68.7
absent 16 67.0 0.7915
*statistically significant difference
Table III. The results of treatment in a group of 31 patients with “mixed” mucinous breast carcinoma type,
and selected populational and clinical characteristics
Population or clinical characteristics No. of treated patients Actuarial 10-year p
cancer free survival in % (log-rank test)
* age:
under 50 14 30.0
51-60 3 0.0
over 60 14 53.3 0.0002
* menopausal status:
premenopausal 11 18.2
menopausal and postmenopausal 20 47.2 0.0107
Localisation of tumour in the breast:
Outer quadrants 22 24.6
Other parts of the breast 9 44.4 0.8181
*clinical nodal status (N):
N0 14 62.9
N1 14 25.7
N2 3 33.3 0.1056
*tumour grading acc. To TNM:
I°+ II°A 15 64.0
II°B 9 22.2
III° 7 17.9 0.1472
Size of mass in the breast assessed by a pathologist in operation
material (pT):
Up to 4 cm 21 50.3
Over 4 cm 10 25.0 0.1695
* microscopic nodal status (pN):
pN0 14 71.4
pN+(1-3) 5 0.0
pN+(>3) 12 19.7 0.5711
Total 50 38.7
* statistically significant differences, log-rank test, p<0.05
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stically significant chance of 10-year cancer-free survival
was observed in patients over 60 years of age, menopausal
or postmenopausal.
The treatment results by MIB-1 index, p53 and c-
-erb B2 expression, and the presence of hormonal recep-
tors in a group of patients with mixed mucinous breast
carcinoma type are presented in Table IV.
Table IV does not show any of the immunohistoche-
mically evaluated factors to have statistically significant ef-
fect on cancer free survival.
Table V presents treatment results in a studied group
of 81 patients with mucinous carcinoma of the breast, by
type of surgery.
The disparity between survival of patients treated
with Patey or Halstead methods should be explained by
different clinical composition of the compared groups;
84% of patients operated by Halstead method had stage
III disease.
Reviewing the data shown in Table VI it should
be noted that in the entire studied group, statistically
significant, unfavourable influence on 10-year symptom-
-free survival in the multivariate Cox model was obse-
rved in patients with mixed mucinous breast carcinoma ty-
pe, under 60 years of age, and clinically axillary positive.
Table VII shows that in the group of patients with
pure mucinous breast carcinoma type only positive axilla-
Table IV. The results of treatment of “mixed type” of 31 patients and immunohistochemical evaluations
Discriminants No. of treated patients Actuarial 10-year p
cancer free survival in % (log-rank-test)
MIB-1 index
≤ 14 12 50.0
>14 19 31.6 0.2784
* p53 gene expression
yes 4 25.0
no 27 65.8 0.1442
c-erb B2 gene expression:
yes 4 37.5
no 27 35.6 0.5922
Oestrogen receptor:
present 25 34.5
absent 6 31.3 0.7857
Progesterone receptor:
present 17 32.4
absent 14 55.6 0.5494
Table V. The results of treatment and the type of surgery
Type of surgery No. of treated patients Actuarial 10-year cancer free survival in %
Halsted surgery 25 40.0
Patey surgery 54 69.6
Tumorectomy (followed by irradiation) 2 100.0
Total 81 60.5
Table VI. The results of a multivariate analysis of prognostic factor in whole group of 81 patients
Variable Variant Relative risk Significance p for relative risk
microscopic mucinous type Pure 1.00 -
Mixed 4.50 0.0013
age of patients ≤60 4.42 0.0013
>60 1.00 -
clinical axillary status N0 1.00 -
N1 3.60 0.0151
N2 25.86 0.0000
Table VII. The results of multivariate analysis of prognostic factors in a group of 50 patients with “pure” mucinous carcinoma of the breast
Variable Variant Relative risk Significance p for relative risk
Clinical axillary status N0 1.00
N1 5.47 0.0670
N2 23.18 0.0038
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ry metastases in N2 advanced level have a statistically si-
gnificant, unfavourable effect on 10-year cancer-free su-
rvival in a multivariate Cox model.
Table VIII shows, that in a group of patients with
mixed mucinous breast carcinoma type, only the patients
age – below 60 had astatistically significant, unfavourable
effect on 10-year cancer-free survival in a multivariate
Cox model.
Reviewing the data presented in Tables VI, VII, VIII
it can be stated that the independent prognostic factors
are:
– in the entire group of patients with mucinous carci-
noma of the breast: microscopic type, patient` s age
and clinical axillary status,
– in the group of patients with pure type of mucinous
carcinoma of the breast: clinical axillary status,
– in the group with mixed mucinous breast carcinoma ty-
pe: patient` s age.
C a u s e s  o f  t r e a t m e n t  f a i l u r e
By the time this study was completed, therapy was unsuc-
cessful in 28 patients of the entire assessed group. Pa-
tients' follow-ups and causes of treatment failure are pre-
sented in Table IX.
Discussion
Analysis of the clinical material has been made, covering
81 women with mucinous carcinoma of the breast who
had received initial surgical treatment at the Oncology
Centre, Cracow Branch, in the years 1952-1993. This ana-
lysis served as a basis for achieving the objectives of the
present study.
Po p u l a t i o n a l  a n d  c l i n i c a l  f e a t u r e s  o f
m u c i n o u s  a l  c a r c i n o m a  o f  t h e  b r e a s t
The characteristic populational and clinical features of
mucinous carcinoma of the breast found in the studied
group of patients, are as follows:
– mean age – 62 years (30-84),
– patients being menopausal or postmenopausal,
– mean time of symptoms duration -8 months (1-36),
– most common localisation in the outer quadrant of
the breast (59.3%),
– in over 70% of patients the lump in the breast (pT) not
larger than 4 cm,
– in over 60% of patients, microscopically negative axil-
lary nodes.
In the literature, the mean age of patients with muci-
nous carcinoma of the breast ranges from 50 to 68 years
[5, 9, 22, 43] however, a majority of authors stress that it
usually exceeds 60 years [1]; acc. to Clayton [22] it is 63
years, acc. to Fentiman [9] – 62 years. All authors agree
that patients with mucinous carcinoma of the breast are
older than patients with ductal infiltrating malignancy
[1, 22].
The literature also confirms the author`s observa-
tions that most mucinous carcinoma patients are either
menopausal or postmenopausal [1, 9, 22]; in the material
studied by Fentiman et al. [9] such patients constituted
82%, by Andre et al. [1] – 83.6%, and by Clayton [22] –
89%. Such clinical features of mucinous carcinoma of
the breast found in the studied group of patients as: time
of symptoms duration, most common localisation of tu-
mour in the outer quadrants, and a high percentage of
low advancement cases are fully supported by reports gi-
ven literature [1, 9, 21, 22, 43].
Within the studied group, in over 70% of patients,
the lump in the breast (pT) was not bigger than 4 cm,
while its mean size was 3.6 cm. In the material investiga-
ted by Clayton [22) the mean size of lump in the breast
was 3.2 cm; by Brennan [5] – 3.8 cm, by Fentiman et al. [9]
– 3 cm, by Andre et al. [1] – 3.7 cm. In the material of Ko-
maki et al. in 53.6% of patients the lump in the breast was
smaller than 02 cm, and in 37.8% it ranged from 2 to
5 cm.
Over 60% of patients in the described group had no
microscopically detected axillary metastases; Bren-
nan`s material [5] comprised 68% of such patients, Andre
et al.`s [1] – 68.3%.
Table VIII. The results of a multivariate analysis of prognostic factors in a group of 31 patients with “mixed” mucinous carcinoma of the breast
Variable Variant Relative risk Significance p for relative risk
Age of patients ≤60 6.76
>60 1.00 0.0161
Table IX. Follow-up and causes of treatment failure in 28 patients from the studied group
Follow-up and causes of treatment failure No of patients
No %
distant mucinous metastases 17 60.7
distant mucinous metastases + loco-regional recurrence 5 17.9
loco-regional mucinous recurrence 2 7.1
tumour of the opposite breast (ductal infiltrating) 1 3.6
other causes 3 10.7
Total 28 100.0
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In the studied group of patients, definite differences
were found between the clinical outcomes of pure and
mixed types of mucinous breast carcinoma:
– patients with pure type were statistically significantly
older than patients with mixed type (68% of patients
over 60 years of age compared to 45%). This observa-
tion is confirmed by other reports [1, 20, 33],
– the percentage of premenopausal women was nearly
double in the group of patients with mixed type (35.5%
as compared to 18%),
– the percentage of patients with the lump in the breast
exceeding 4 cm was higher in the group of patients
with mixed type of mucinous carcinoma of the breast
(32.3% vs. 28%). A majority of authors stress that in
patients with mixed mucinous type, the lumps in the
breasts are usually considerably bigger than in patients
with pure mucinous type [9]; in the material studied by
Toikkanen and Kujari (153) the percentage of lumps
over 5 cm in size was 22% in the pure type group, and
48% in the mixed type group. In Brennan`s material,
the mean lump size was 1.96 cm in pure and 2.62 cm in
mixed type [5], in Fentiman et al.`s material [9] – 2.2
cm and 3.2 cm. Only a few authors did not find any dif-
ferences in this respect [1],
– in the studied group of patients with mixed type of
mucinous carcinoma of the breast, axillary metastases
were statistically more common on microscopic exami-
nation (pN+= 54.8% vs. 30%). This phenomenon is
confirmed by numerous data from literature [2]; in
the material studied by Rasmussen axillary metastases
were found in 3% patients with pure and in 33% of
patients with mixed type of mucinous carcinoma of
the breast; by Komaki et al. respectively 15% and
46%, Scopsi et al. – 29% and 65%, Andre et al. [1] –
26% and 41%, Fentiman et al. [9] – 14% and 46%.
Generally, in the literature, axillary metastases are
found in 3-29% of patients with pure, and in 33-86%
of patients with mixed carcinoma of the breast [1, 8, 9,
20].
Summing up the results of own studies and the data
from literature, it should be concluded that mucinous
carcinoma of the breast, and particularly its pure form,
present specific population and clinical characteristics:
a more advanced age of patients and relatively slow
growth – with long time of symptoms duration, low per-
centage of large lumps in the breast and metastases to
axillary nodes. The clinical outcome in mixed type of mu-
cinous carcinoma is similar to the clinical outcome in
ductal infiltrating carcinoma.
Fe a t u r e s  o f  m u c i n o u s  c a r c i n o m a  o f  t h e
b r e a s t ,  d e t e r m i n e d  b y
i m m u n o h i s t o c h e m i c a l  e v a l u a t i o n
Immunohistochemical evaluation performed in the di-
scussed group of patients revealed the following characte-
ristic features of mucinous breast carcinoma:
– low MIB-1 index which, in over a half of the patients,
does not exceed 14,
– low percentage of tumours presenting p53 and c-erb B2
expression – 12.3% and 9.9% respectively,
– over 90% of patients being oestrogen receptor positive
and over 60% – progesterone receptor positive.
In the available literature I have not found any re-
ports analysing the role of MIB-1 index selectively for
mucinous breast carcinoma patients. There are reports di-
scussing this problem in reference to the whole group of
patients with mammary cancers [40, 41, 44]. Meyer et
al., studying another index of neoplastic cell prolifera-
tion, i.e. the fraction of cells in the S-phase, concluded
that in mucinous breast carcinoma it was low. Furthermo-
re, literature does not provide reports offering selective
evaluation of p53 and c-erb B2 expression in mucinous
carcinoma of the breast, while there are obviously nu-
merous reports discussing this problem in reference to
the whole group of mammary cancer patients [39, 40,
45, 46].
The data from literature support my observation
that a majority of mucinous breast carcinoma patients
are hormone receptor positive [2, 47].
The investigated material was also used to compare
the immunohistochemical evaluation in two groups of
patients: those with pure and those with mixed type muci-
nous breast carcinoma. The comparison revealed the fol-
lowing statistically significant findings in the mixed type
group:
– more patients with MIB-1 index over 14 (61.3% vs.
38%),
– fewer oestrogen receptor positive patients (80.6% vs.
98%).
No cytofluorometric evaluation was performed in
the studied group; literature provides numerous data in
this respect which does not raise any serious reservations.
It is generally assumed that only a small percentage of
mucinous breast carcinomas, particularly their pure ty-
pe, is aneuploid (2). It has been pointed out that aneu-
ploid tumours occur mainly in mixed type mucinous
carcinoma patients and that aneuploidy positively correla-
tes with axillary metastases and absence of oestrogen re-
ceptor (2).
D e t e r m i n i n g  p r o g n o s t i c  f a c t o r s
Univariate analysis of prognostic factors revealed that si-
gnificantly unfavourable influence on 10-year cancer-free
survival in the entire group of patients, was exerted by: pa-
tients` age below 60, premenopausal status, clinically me-
tastatic axillary nodes, stages IIB and III acc. to TNM,
lump size in the breast (pT) over 4 cm, microscopically
positive axillary nodes, mixed type of mucinous carcinoma
of the breast and the presence of p 53 expression.
A multivariate analysis of prognostic factors using
the Cox method showed that in the total group of pa-
tients studied, independent unfavourable prognostic fac-
tors were: mixed type of mucinous carcinoma, age below
60 and clinically positive axillary nodes. In the pure type
group, the sole prognostic factor was clinical axillary sta-
tus and in the mixed type group – age.
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According to the data obtained from literature, the
basic prognostic factor in patients with mucinous carcino-
ma of the breast is the microscopic status of axillary nodes
[1, 22, 32]. In the presented group of patients, quite une-
xpectedly, but without doubt, this basic prognostic fac-
tor turned out to be not the microscopic but the clinical
status of axillary nodes; even clinical stage N1 meant po-
orer prognosis.
The second prognostic factor generally approved in
literature formucinous breast carcinoma patients is the
microscopic type of tumour. Similarly as in the presented
study, the mixed type is considered to be worse progno-
sing than the pure type [1, 4, 10, 24, 25]. Age being a pro-
gnostic factor, revealed in the studied group, finds
support only in the conclusions reached by Avisar et al. [2]
who advocate higher frequence of positive axillary me-
tastases in young patients with mucinous breast carci-
noma.
Some authors suggest the lump size in the breast to
be a prognostic factor, with 5 cm treated as a cut-off value
[1, 22]. In the studied material, similarly as in the material
investigated by Avisar et al. [2], this was not a significant
prognosticator. Some authors stipulate the existence of
other potential prognostic factors in patients with mucino-
us carcinoma of the breast, e.g. differentiation and cellu-
larity level of the tumour, amount of mucin, argyrophylic
level, presence of DCIS, neuroendocrine markers (NSE,
SYN) etc. [1, 9, 20, 22, 23, 48].
E v a l u a t i o n  o f  t h e  e f f e c t i v e n e s s  i n  t h e
t r e a t m e n t  o f  p a t i e n t s  w i t h  m u c i n o u s
c a r c i n o m a  o f  t h e  b r e a s t
The studies performed have found initial operational the-
rapy to be an effective procedure in patients with mucino-
us breast carcinoma. In the assessed group, the actuarial
10-year survival was 0.60, for pure mucinous type patients
– 0.74, while for mixed type patients – 0.39. In the litera-
ture, cancer free 5-year survival in the mucinous breast
carcinoma group ranges from 68% to 100% [5, 30-32,
47] and 10-year survival, from 55% to 77% [1, 5, 22, 47],
mainly in relation to the ratio of pure to mixed type in the
clinical material studied.
A majority of authors report that survival of mucino-
us breast carcinoma patients is longer than that obtained
in the group of patients with the most common microsco-
pical type of breast tumour – the ductal infiltrating carci-
noma [9, 22]; this is true, in particular, for the pure muci-
nous type [1, 2, 9, 21].
According to a great many authors, the mixed type of
mucinous carcinoma of the breast is related to a signifi-
cantly worse prognosis than the pure type, and can be
compared, in this respect, to the ductal infiltrating carci-
noma [1, 4, 10, 24, 25]. Toikkanen and Kujari obtained
79% of cancer free 10-year survival in pure mucinous ty-
pe group, 41% in mixed group, and 41% in the ductal
infiltrating carcinoma patients. In the group presented
by Andre et al. [1], 10-year disease free survival was obser-
ved in 74.8% of pure mucinous type patients and 20.3%
of mixed type patients; in the group of Fentiman et al. [9]
these values were 87% and 54% respectively. 15-year su-
rvival in the group described by Toikkanen and Kujari
amounted to 85% in the pure and 63% in the mixed gro-
up, while 20- year survival presented by Scopsi et al. was
70% and 38% respectively, with 46% for ductal infiltra-
ting carcinoma group.
Concluding, literature presents 10-year survival in
the mixed mucinous breast carcinoma type as 20-66%,
and in the pure type as 75 – 100% [1, 9, 24]. Conside-
ring that the mixed type comprises the ductal infiltrating
component while the pure type does not, it should not
be surprising that both the clinical outcome and progno-
sis bring the mixed type close to the ductal infiltrating
type.
Opinions suggesting that mixed mucinous breast car-
cinoma has the same prognostic features and does not
differ clinically from the pure type [2] are extremely rare
in literature.
D e t e r m i n i n g  o p t i m u m  t h e r a p y  f o r
p a t i e n t s  w i t h  m u c i n o u s  c a r c i n o m a  o f  t h e
b r e a s t
In the past decades, women with mucinous carcinoma of
the breast were initially treated with radical mastectomy;
only few authors decided on simple mastectomy when
treating older and node negative patients. The reports
of Wasserman et al., Ucla et. al. and of Kurtz et al. from
the eighties, showed that routine radical mastectomy in
mucinous breast carcinoma patients was not justified; at
present, mucinous breast carcinoma patients are gene-
rally treated with breast conservation therapy (lumpecto-
my plus irradiation) [2]. It is now obvious that patients
with mixed type of mucinous breast carcinoma should
receive the same therapy as patients with ductal infiltra-
ting carcinoma at the corresponding stage, both in re-
spect of local therapy and postoperative irradiation, che-
mo- and hormonotherapy. This conclusion is supported by
own observations (only 38.7% of patients were cured) as
well as numerous other reports [10, 22, 25].
Patients with pure mucinous carcinoma of the breast
and negative axillary nodes are generally assumed to ha-
ve very good prognosis (over 90% complete recoveries
were obtained) and they do not require any adjuvant the-
rapy [1, 4, 9, 21, 24, 30-32]. In own material, out of 35
women with pure type and negative axillary nodes who
did not receive adjuvant therapy only two patients (5.5%)
died of mucinous breast carcinoma. All 15 patients in
this group with lump size in the breast (pT) not exce-
eding 2 cm and with no axillary node involvement, survi-
ved 10 years without cancer.
Recently it has even been suggested that if the tumo-
ur size in the breast of a patient with pure type of mucino-
us breast carcinoma does not exceed 2 cm, the therapeu-
tic procedure may be limited to the excision of the lump
with healthy tissue margin [9]. This opinion might be so-
mewhat far-reached, but it is evident that the treatment of
choice in patients with pure type of mucinous carcino-
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ma of the breast would be breast conservation surgery, i.e.
lumpectomy with axillary lymphadenectomy, followed by
irradiation. In case of lumps not larger than 2 cm and
absence of clinical features of axillary involvement, so-
me authors suggest not to excise the axillary nodes [1, 2,
9], although there are many who oppose this opinion [22].
Own studies (only slightly over 40% of cured pa-
tients), as well as numerous reports by other authors,
show that women with pure type of mucinous breast car-
cinoma and positive axillary nodes should receive the sa-
me therapy as patients with mixed type (and, in result, the
same as patients with ductal infiltrating carcinoma at the
corresponding stage). It is obviously recommended, in
accordance with the current general guidelines, to apply
breast conservation therapy with subsequent chemo-
and/or hormonotherapy [1, 9, 20].
The basic cause of treatment failure in the studied
group was the development of distant metastases, which is
in accord with the data from literature [1, 2, 9, 20]. Some
authors report cerebral infarction caused by mucin embo-
lism that occurred in patients with mucinous carcinoma of
the breast [49]. Further two patients were lost due to ce-
rebral embolisms of unknown etiology.
Many authors describe late recurrence of mucinous
breast carcinoma, 10 years or more after surgery [8, 22,
50]. In Gerschickter`s group, 14 of 59 patients had muci-
nous breast carcinoma recurrence within 6 to 18 years
from diagnosis. In the material of Rosen and Wang, 42%
of recurrences were found 12 years after therapy. In pa-
tients studied by Donegan and Spratt, out of 15 patients
who died of mucinous breast carcinoma, 6 died between
10 to 20 years after operation. Clayton demonstrated that
the mean survival of patients who died of mucinous carci-
noma of the breast was 11 years [22]. The latest recurren-
ces of the malignancy were described by Lee and Terry –
25 years, and by Sharnhorst and Huntrakoon – 30 years
after diagnosis. In such situation, some authors stress the
need of long-term observation of patients with mucinous
breast carcinoma (15-20 years), which is often impossible
due to the advanced age of majority of patients at the ti-
me of diagnosis [22]. In the studied group, observed from
5 to 46 years, no late recurrences were noted; similar ab-
sence of late recurrences was shown by Komaki et al.,
Toikkanen and Kujari, Fentiman et al., Wulsin and Schre-
iber, Rosen et al. [9].
Conclusions
1. The specific population and clinical features of mucino-
us breast carcinoma found in the evaluated group of
patients are:
– mean age – 62 years (30-84),
– over 3/4 of patients being menopausal or postmeno-
pausal,
– mean time of symptoms duration – 8 months (1-36),
– most common localisation of tumour in the outer
quadrants of the breast,
– in over 70% of patients, the lump size in the breast
(pT) not exceeding 4 cm,
– in over 60% of patients, microscopically negative
axillary nodes.
2. The specific features of mucinous carcinoma of the
breast found on immunuhistochemical evaluations are:
– relatively low MIB-1 index which, in over a half of
the patients, does not exceed 14 (2-46),
– over 90% of patients being oestrogen receptor po-
sitive and over 60% – progesterone receptor posi-
tive,
– low percentage of tumours presenting p53 and
c-erb B2 expression – 12.3% and 9.9% respecti-
vely.
3. Independent unfavourable prognostic factors in pa-
tients with mucinous carcinoma of the breast are: pa-
tient`s age below 60, clinically positive axillary nodes
and mixed tumour type.
4. Surgical treatment allows to obtain over 60% of 10-
-year cancer free survival in patients with mucinous
carcinoma of the breast, of which 74% in the pure,
and 39% in the mixed mucinous type group. The basic
cause of treatment failure is generalisation of the ma-
lignant process.
5. All patients with mixed mucinous breast carcinoma
type and those patients with pure mucinous type who
are axillary positive, should receive the same treat-
ment as patients with ductal infiltrating carcinoma at
the corresponding stage of clinical advancement, both
local and adjuvant.
6. For patients with pure mucinous type and negative
axillary nodes, breast conservation therapy should be
the main option, and it may be considered not to apply
adjuvant systemic therapy.
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